Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM ISIN · CA4236943060 LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 576 across all filing types
Latest filing 2022-09-14 Board/Management Inform…
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Renzo Cecere to the Scientific Advisory Board of Hemostemix. It contains no financial statements, no regulatory filings, no voting results, no capital or financing updates, no earnings data, and no detailed management or governance reports. It is a corporate announcement about a management/scientific advisory board appointment. Therefore, it fits best under Board/Management Information (MANG). The document length is 9419 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content. Hence, the classification is MANG with high confidence.
2022-09-14 English
News release - English.pdf
Investor Presentation Classification · 95% confidence The document is a press release announcing Hemostemix's presentation at the Emerging Growth Conference. It invites investors and analysts to attend the presentation and provides background information about the company and its products. There is no detailed financial data, no regulatory filing, no voting results, no management or board changes, no audit or earnings report, and no mention of a report being attached or published. The content is primarily an investor presentation announcement. Given the nature of the document as an announcement of a presentation event, the most appropriate classification is Investor Presentation (IP). The document length is 6721 characters, which supports it being a full announcement rather than a brief notice. Confidence is high as the content clearly matches the description of an investor presentation announcement.
2022-09-14 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Thomas Abraham as President of PreCerv Inc., a subsidiary of Hemostemix. It contains biographical details, company background, and forward-looking statements about product development and commercialization. There are no financial statements, regulatory filings, voting results, or detailed financial data. The content focuses on management appointment and business development rather than financial results or governance rules. Therefore, the document fits best under Board/Management Information (MANG). The document length (8659 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-09-13 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, purchaser information, and exemption relied upon. This form is a regulatory filing used in Canada to report exempt distributions of securities. It is not an annual report, earnings release, or any other financial report but a specific regulatory compliance document related to securities distribution. The document is lengthy (15,000 characters) and contains substantive data about the distribution, but it is not a financial report or management discussion. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory compliance documents that do not fit other categories.
2022-09-06 English
Material change report - English.pdf
Regulatory Filings
2022-09-01 English
News release - English.pdf
Regulatory Filings
2022-09-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.